Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA, et al. Current and emergent therapy options for advanced squamous cell lung cancer. J Thorac Oncol. 2018;13(2):165–83. https://doi.org/10.1016/j.jtho.2017.11.111.

Article  CAS  Google Scholar 

Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519–25. https://doi.org/10.1038/nature11404.

Article  CAS  Google Scholar 

Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet (London, England). 2021;398(10308):1344–57. https://doi.org/10.1016/S0140-6736(21)02098-5.

Article  CAS  Google Scholar 

Rousseau A, Bertolotti A. Regulation of proteasome assembly and activity in health and disease. Nat Rev Mol Cell Biol. 2018;19(11):697–712. https://doi.org/10.1038/s41580-018-0040-z.

Article  CAS  Google Scholar 

Wang S, Wang T, Yang Q, Cheng S, Liu F, Yang G, et al. Proteasomal deubiquitylase activity enhances cell surface recycling of the epidermal growth factor receptor in non-small cell lung cancer. Cell Oncol (Dordr). 2022;45(5):951–65. https://doi.org/10.1007/s13402-022-00699-0.

Article  CAS  Google Scholar 

Tong L, Shen S, Huang Q, Fu J, Wang T, Pan L, et al. Proteasome-dependent degradation of Smad7 is critical for lung cancer metastasis. Cell Death Differ. 2020;27(6):1795–806. https://doi.org/10.1038/s41418-019-0459-6.

Article  CAS  Google Scholar 

Liu J, Guan D, Dong M, Yang J, Wei H, Liang Q, et al. UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination. Nat Cell Biol. 2020;22(9):1056–63. https://doi.org/10.1038/s41556-020-0559-z.

Article  CAS  Google Scholar 

Collins GA, Goldberg AL. The logic of the 26S proteasome. Cell. 2017;169(5):792–806. https://doi.org/10.1016/j.cell.2017.04.023.

Article  CAS  Google Scholar 

Kimura Y, Tanaka K. Regulatory mechanisms involved in the control of ubiquitin homeostasis. J Biochem. 2010;147(6):793–8. https://doi.org/10.1093/jb/mvq044.

Article  CAS  Google Scholar 

Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5(1):11. https://doi.org/10.1038/s41392-020-0107-0.

Article  CAS  Google Scholar 

Lu M, Chen W, Zhuang W, Zhan X. Label-free quantitative identification of abnormally ubiquitinated proteins as useful biomarkers for human lung squamous cell carcinomas. EPMA J. 2020;11(1):73–94. https://doi.org/10.1007/s13167-019-00197-8.

Article  Google Scholar 

Bhat SA, Vasi Z, Adhikari R, Gudur A, Ali A, Jiang L, et al. Ubiquitin proteasome system in immune regulation and therapeutics. Curr Opin Pharmacol. 2022;67:102310. https://doi.org/10.1016/j.coph.2022.102310.

Article  CAS  Google Scholar 

Çetin G, Klafack S, Studencka-Turski M, Krüger E, Ebstein F. The ubiquitin-proteasome system in immune cells. Biomolecules. 2021;11(1). https://doi.org/10.3390/biom11010060.

Kammerl IE, Meiners S. Proteasome function shapes innate and adaptive immune responses. Am J Physiol Lung Cell Mol Physiol. 2016;311(2):L328–36. https://doi.org/10.1152/ajplung.00156.2016.

Article  Google Scholar 

Wang P, Chen Y, Wang C. Beyond tumor mutation burden: tumor neoantigen burden as a biomarker for immunotherapy and other types of therapy. Front Oncol. 2021;11:672677. https://doi.org/10.3389/fonc.2021.672677.

Article  CAS  Google Scholar 

Xuan DTM, Wu C-C, Kao T-J, Ta HDK, Anuraga G, Andriani V, et al. Prognostic and immune infiltration signatures of proteasome 26S subunit, non-ATPase (PSMD) family genes in breast cancer patients. Aging. 2021;13(22):24882–913. https://doi.org/10.18632/aging.203722.

Article  CAS  Google Scholar 

Xu J, Brosseau J-P, Shi H. Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy. Oncogene. 2020;39(48):7106–13. https://doi.org/10.1038/s41388-020-01491-w.

Article  Google Scholar 

Zengin T, Önal-Süzek T. Comprehensive profiling of genomic and transcriptomic differences between risk groups of lung adenocarcinoma and lung squamous cell carcinoma. J Personalized Med. 2021;11(2). https://doi.org/10.3390/jpm11020154.

Liu Z, Wang W, Zhou Y, Li L, Zhou W. PSMA1, a poor prognostic factor, promotes tumor growth in lung squamous cell carcinoma. Dis Markers. 2023;2023:5386635. https://doi.org/10.1155/2023/5386635.

Article  CAS  Google Scholar 

Zhan X, Lu M, Yang L, Yang J, Zhan X, Zheng S, Guo Y, Li B, Wen S, Li J, Li N. Ubiquitination-mediated molecular pathway alterations in human lung squamous cell carcinomas identified by quantitative ubiquitinomics. Front Endocrinol (Lausanne). 2022;13:970843. https://doi.org/10.3389/fendo.2022.970843.

Article  Google Scholar 

Amit S, Ben-Neriah Y. NF-kappaB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol. 2003;13(1):15–28.

Article  CAS  Google Scholar 

Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, et al. B7–H3 and B7–H4 expression in non-small-cell lung cancer. Lung Cancer. 2006;53(2):143–51.

Article  Google Scholar 

Song X, Zhou Z, Li H, Xue Y, Lu X, Bahar I, et al. Pharmacologic suppression of B7–H4 glycosylation restores antitumor immunity in immune-cold breast cancers. Cancer Discov. 2020;10(12):1872–93. https://doi.org/10.1158/2159-8290.CD-20-0402.

Article  CAS  Google Scholar 

Baravalle G, Park H, McSweeney M, Ohmura-Hoshino M, Matsuki Y, Ishido S, et al. Ubiquitination of CD86 is a key mechanism in regulating antigen presentation by dendritic cells. J Immunol. 2011;187(6):2966–73. https://doi.org/10.4049/jimmunol.1101643.

Article  CAS  Google Scholar 

Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017;47(5):765–79. https://doi.org/10.1002/eji.201646875.

Article  CAS  Google Scholar 

Corcoran K, Jabbour M, Bhagwandin C, Deymier MJ, Theisen DL, Lybarger L. Ubiquitin-mediated regulation of CD86 protein expression by the ubiquitin ligase membrane-associated RING-CH-1 (MARCH1). J Biol Chem. 2011;286(43):37168–80. https://doi.org/10.1074/jbc.M110.204040.

Article  CAS  Google Scholar 

Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017;549(7670):106–10. https://doi.org/10.1038/nature23669.

Article  ADS  CAS  Google Scholar 

Burr ML, Sparbier CE, Chan Y-C, Williamson JC, Woods K, Beavis PA, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549(7670):101–5. https://doi.org/10.1038/nature23643.

Article  ADS  CAS  Google Scholar 

Lim S-O, Li C-W, Xia W, Cha J-H, Chan L-C, Wu Y, et al. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016;30(6):925–39. https://doi.org/10.1016/j.ccell.2016.10.010.

Article  CAS  Google Scholar 

Ding L, Chen X, Zhang W, Dai X, Guo H, Pan X, et al. Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. J Clin Investigation. 2023;133(1). https://doi.org/10.1172/JCI154754.

Debeljak Ž, Dundović S, Badovinac S, Mandić S, Samaržija M, Dmitrović B, et al. Serum carbohydrate sulfotransferase 7 in lung cancer and non-malignant pulmonary inflammations. Clin Chem Lab Med. 2018;56(8):1328–35. https://doi.org/10.1515/cclm-2017-1157.

Article  CAS  Google Scholar 

Hung C-C, Lin C-H, Chang H, Wang C-Y, Lin S-H, Hsu P-C, et al. Astrocytic GAP43 induced by the TLR4/NF-κB/STAT3 axis attenuates astrogliosis-mediated microglial activation and neurotoxicity. J Neurosci. 2016;36(6):2027–43. https://doi.org/10.1523/JNEUROSCI.3457-15.2016.

Article  CAS  Google Scholar 

Zhang F, Ying L, Jin J, Feng J, Chen K, Huang M, et al. GAP43, a novel metastasis promoter in non-small cell lung cancer. J Transl Med. 2018;16(1):310. https://doi.org/10.1186/s12967-018-1682-5.

Article  CAS  Google Scholar 

Gebhardt A, Habjan M, Benda C, Meiler A, Haas DA, Hein MY, et al. mRNA export through an additional cap-binding complex consisting of NCBP1 and NCBP3. Nat Commun. 2015;6:8192. https://doi.org/10.1038/ncomms9192.

Article  ADS  CAS  Google Scholar 

Zhang H, Wang A, Tan Y, Wang S, Ma Q, Chen X, et al. NCBP1 promotes the development of lung adenocarcinoma through up-regulation of CUL4B. J Cell Mol Med. 2019;23(10):6965–77. https://doi.org/10.1111/jcmm.14581.

Article  CAS  Google Scholar 

Li X, Zhu G, Li Y, Huang H, Chen C, Wu D, et al. LINC01798/miR-17-5p axis regulates ITGA8 and causes changes in tumor microenvironment and stemness in lung adenocarcinoma. Front Immunol. 2023;14:1096818. https://doi.org/10.3389/fimmu.2023.1096818.

Article  CAS  Google Scholar 

Wang Y, Li Y, Jiang X, Gu Y, Zheng H, Wang X, et al. OPA1 supports mitochondrial dynamics and immune evasion to CD8+ T cell in lung adenocarcinoma. Peer J. 2022;10:e14543. https://doi.org/10.7717/peerj.14543.

Article  CAS  Google Scholar 

Abaza Y, Kantarjian HM, Faderl S, Jabbour E, Jain N, Thomas D, et al. (2018) Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018;93(1):91–9. https://doi.org/10.1002/ajh.24947.

Article  CAS  Google Scholar 

Oo ZY, Proctor M, Stevenson AJ, Nazareth D, Fernando M, Daignault SM, et al. Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine. Mol Oncol. 2019;13(7):1503–18. https://doi.org/10.1002/1878-0261.12497.

Article  CAS  Google Scholar 

Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, et al. Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. EMBO Mol Med. 2019;11(7):e9982. https://doi.org/10.15252/emmm.201809982.

Article  CAS  Google Scholar